Armata Pharmaceuticals is a biotechnology company developing bacteriophage therapeutics—naturally occurring viruses that target and kill specific antibiotic-resistant bacteria while preserving the human microbiome—as an alternative to broad-spectrum antibiotics for difficult-to-treat infections. The company combines proprietary expertise in identifying, characterizing, and engineering bacteriophages with proprietary manufacturing capabilities to advance a clinical pipeline of high-purity phage cocktail candidates for pulmonary and bloodstream infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, among other pathogens. Armata retains worldwide commercial rights to its candidates and intends to commercialize them either through partnerships with established pharmaceutical companies or by building its own sales infrastructure following regulatory approval.